The Board in its meeting held on May 19, 2026 has approved the allotment of 14,81,250 equity shares to eligible employees upon exercise of options vested under Anthem Employee Stock Option Plan 2024
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anthem Biosciences board approved audited standalone FY26 results showing revenue of Rs 2,089 crore and PAT of Rs 671 crore, representing strong year-on-year growth. The board recommended a final dividend of INR 2.00 per equity share (100% payout on face value) for FY26, subject to shareholder approval at the July 22, 2026 AGM. The company also allotted 14,81,250 equity shares to employees under the ESOP 2024 plan, increasing paid-up capital to Rs 1,12,63,90,202. Additionally, the board approved continuation of Mr. Ravikant Uppal as Independent Director beyond age 75 and re-appointment of Mr. Ravindra Chandrappa as Whole-Time Director. Statutory auditors gave unmodified opinion on both standalone and consolidated financials.
The strong financial performance with revenue and profit growth, combined with shareholder-friendly dividend payout, signals positive momentum. The ESOP allotment causes minor dilution (~0.26%) but aligns employee interests with shareholders. The unmodified audit opinion reinforces financial credibility.